Parenteral Drugs (India) revenue surged on 48.0%
16-06-2016 • About Parenteral Drugs (India) (
$PARENTLD) • By InTwits
Parenteral Drugs (India) reported FY2016 financial results today. Overall the company's long term financial model is characterised by the following facts: It operates with medium-size leverage: Net Debt/EBITDA is 1.2x while industry average is -0.1x.
Below you can find a comprehensive analysis of the key data driving the company's performance and the stock price.
Revenue and profitability
Parenteral Drugs (India)'s Revenue surged on 48.0%.
Net Income margin dropped on 14.0 pp from -30.7% to -44.8% in FY2016.
Financial and operational results
Parenteral Drugs (India) ($PARENTLD) key annual financial indicators| mln. INR | 2012 | 2013 | 2014 | 2015 | 2016 | 2016/2015 |
|---|
P&L
|
|---|
| Revenue | 3,325 | 3,274 | 2,737 | 1,759 | 2,603 | 48.0% |
| EBITDA | 144 | -138 | | 134 | | |
| Net Income | -534 | -1,078 | -452 | -541 | -1,165 | |
Balance Sheet
|
|---|
| Cash | 63 | 69 | | | | |
| Short Term Debt | 1,599 | 836 | | | | |
| Long Term Debt | 2,230 | 4,003 | | | | |
Cash flow
|
|---|
| Capex | 1,481 | 212 | | | | |
Ratios
|
|---|
| Revenue growth | -31.0% | -1.5% | -16.4% | -35.7% | 48.0% | |
| EBITDA growth | -71.0% | -195.7% | | | | |
|
|---|
| EBITDA Margin | 4.3% | -4.2% | | 7.6% | |
| Net Income Margin | -16.1% | -32.9% | -16.5% | -30.7% | -44.8% | -14.0% |
| CAPEX, % of revenue | 44.5% | 6.5% | | | | |
|
|---|
| ROIC | -0.0% | -4.8% | | | | |
| ROE | -16.1% | -38.1% | | | | |
| Net Debt/EBITDA | 26.1x | | | 0.0x | |
Peers in Pharmaceuticals
Below we provide Parenteral Drugs (India) benchmarking against other companies in Pharmaceuticals industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Alembic Pharmaceuticals ($APLLTD) | - | 3.7% | 22.6% | 10.4% | 53.1% |
| Lincoln Pharmaceuticals ($LINCOPH) | - | 3.8% | 8.5% | 25.9% | 50.4% |
| Torrent Pharmaceuticals ($TORNTPHARM) | - | 17.7% | 32.2% | 13.6% | 42.4% |
| Natco Pharma ($NATCOPHARM) | - | 26.1% | 11.9% | 11.7% | 38.3% |
| Mangalam Drugs & Organics ($MANGALAM) | - | -18.2% | -2.1% | 79.8% | 33.7% |
| |
|---|
| Median (36 companies) | 28.0% | 15.0% | 13.1% | 8.9% | 11.2% |
|---|
| Parenteral Drugs (India) ($PARENTLD) | - | -1.5% | -16.4% | -35.7% | 48.0% |
Top companies by Gross margin, %
| Top | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Dr.Reddy'S Laboratories ($DRREDDY) | - | 52.1% | 57.4% | 57.6% | 59.6% |
| Omega Laboratories ($OMEGALAB) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| |
|---|
| Median (2 companies) | 46.9% | 26.1% | 28.7% | 28.8% | 29.8% |
|---|
Top companies by EBITDA margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Divi'S Laboratories ($DIVISLAB) | 37.2% | 38.2% | 40.2% | 37.4% | 37.5% |
| Hester Biosciences ($HESTERBIO) | - | - | - | 32.9% | - |
| Sun Pharmaceutical Industries ($SUNPHARMA) | 40.8% | 44.3% | 44.9% | 29.2% | 30.6% |
| Natco Pharma ($NATCOPHARM) | 21.5% | 23.2% | 24.9% | 26.2% | 24.1% |
| Dr.Reddy'S Laboratories ($DRREDDY) | 25.8% | 22.9% | 25.1% | 23.2% | 25.8% |
| |
|---|
| Median (53 companies) | 12.8% | 13.1% | 14.5% | 12.1% | 15.5% |
|---|
| Parenteral Drugs (India) ($PARENTLD) | 4.3% | -4.2% | - | 7.6% | - |
Top companies by CAPEX/Revenue, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| J.B.Chemicals & Pharmaceuticals ($JBCHEPHARM) | 10.0% | 5.8% | 6.0% | 6.2% | 15.9% |
| Claris Lifesciences ($CLARIS) | 58.1% | 42.9% | - | 103.1% | 15.8% |
| Marksans Pharma ($MARKSANS) | 1.5% | 1.5% | 0.8% | 4.6% | 14.8% |
| Natco Pharma ($NATCOPHARM) | 24.4% | 16.3% | 14.4% | 14.1% | 13.8% |
| Sun Pharmaceutical Industries ($SUNPHARMA) | 8.9% | 7.5% | 5.7% | 8.6% | 12.2% |
| |
|---|
| Median (27 companies) | 7.6% | 8.3% | 5.8% | 6.1% | 8.4% |
|---|
Top companies by ROIC, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Alembic Pharmaceuticals ($APLLTD) | 27.5% | 29.1% | 41.5% | 35.7% | 62.1% |
| Torrent Pharmaceuticals ($TORNTPHARM) | 26.4% | 30.5% | 33.2% | 19.7% | 44.2% |
| Abbott India ($ABBOTINDIA) | 29.6% | 26.9% | 30.5% | 34.2% | 34.1% |
| Divi'S Laboratories ($DIVISLAB) | 30.6% | 30.4% | 32.3% | 30.5% | 31.9% |
| Jenburkt Pharmaceuticals ($JENBURPH) | 34.1% | 29.0% | 32.4% | 35.3% | 31.4% |
| |
|---|
| Median (60 companies) | 14.0% | 13.2% | 15.0% | 13.2% | 16.3% |
|---|
| Parenteral Drugs (India) ($PARENTLD) | -0.0% | -4.8% | - | - | - |
Top companies by Net Debt / EBITDA
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Jubilant Life Sciences Limited ($JUBILANT) | 4.0x | 3.5x | 3.5x | 6.4x | 3.2x |
| Claris Lifesciences ($CLARIS) | 1.9x | 1.1x | 1.8x | 3.2x | 2.9x |
| Themis Medicare ($THEMISMED) | - | 7.9x | 0.0x | 0.0x | 2.9x |
| Glenmark Pharmaceuticals ($GLENMARK) | 2.7x | 2.1x | 2.2x | 2.5x | 2.2x |
| Dishman Pharmaceuticals & Chemicals ($DISHMAN) | 3.6x | 2.6x | 2.3x | 2.9x | 2.1x |
| |
|---|
| Median (42 companies) | 1.6x | 1.5x | 0.3x | 0.2x | 0.2x |
|---|
